Therefore, we herein investigated the effects of CEP-1347 on malignant meningioma cells, which we recently characterized as a novel inhibitor of MDM4 protein expression that is capable of activating the p53 pathway in cancer cells expressing wild-type p53 [19,20]. The gene discussed is TP53; the disease is meningioma.